{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:09Z","timestamp":1788923889023,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale and Patients concerns:<\/jats:title>\n                    <jats:p>Despite the introduction of varied disease-modifying antirheumatic drugs and biological agents, a substantial proportion of patients remain untreatable. We report a 56-year-old Chinese female patient with a case of refractory rheumatoid arthritis (RA) complicated with multiple myeloma (MM) who was treated successfully with Bortezomib followed by autologous stem cell transplantation (ASCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis and Interventions:<\/jats:title>\n                    <jats:p>We report a 56-year-old Chinese female patient who was diagnosed as RA complicating with MM. She received 4 cycles of Bortezomib-based chemotherapy followed by ASCT. The response of her RA and MM were evaluated after every cycle of Bortezomib-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions and Outcomes:<\/jats:title>\n                    <jats:p>After the first Bortezomib-based chemotherapy cycle, this patient's symptoms were significantly alleviated and thereafter the RA activity continued to improve. After the 4 courses of Bortezomib-based chemotherapy, the C-reactive protein was &lt;0.5\u200amg\/dL and the disease activity score 28-erythrocyte sedimentation rate was 2.0. No hematological or nonhematological side effects were observed during the treatment of Bortezomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Bortezomib might be a new safe and promising drug for refractory RA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000005760","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:06:09Z","timestamp":1483020369000},"page":"e5760","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis"],"prefix":"10.1097","volume":"95","author":[{"given":"Junru","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifen","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-50-20260907","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/s10165-012-0799-2","article-title":"JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"R2-50-20260907","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/eci.12.19","article-title":"Tofacitinib for the treatment of rheumatoid arthritis","volume":"8","author":"Zerbini","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"R3-50-20260907","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/17425255.2013.789500","article-title":"A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis","volume":"9","author":"Bannwarth","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-50-20260907","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","article-title":"Proteasome inhibition: a new anti-inflammatory strategy","volume":"81","author":"Elliott","year":"2003","journal-title":"J Mol Med"},{"key":"R5-50-20260907","first-page":"616","article-title":"Development of proteasome inhibitors in oncology and autoimmune diseases","volume":"11","author":"Bennett","year":"2008","journal-title":"Curr Opin Drug Discov Dev"},{"key":"R6-50-20260907","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheumtol"},{"key":"R7-50-20260907","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","article-title":"Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation","volume":"4","author":"Durie","year":"2003","journal-title":"Hematol J"},{"key":"R8-50-20260907","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology"},{"key":"R9-50-20260907","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s40064-015-0979-6","article-title":"Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease","volume":"4","author":"Mohammed","year":"2015","journal-title":"Springerplus"},{"key":"R10-50-20260907","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R11-50-20260907","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-proteinconjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Ann Rev Biochem"},{"key":"R12-50-20260907","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.biochi.2010.06.023","article-title":"Proteasome inhibitors: dozens of molecules and still counting","volume":"92","author":"De Bettignies","year":"2010","journal-title":"Biochimie"},{"key":"R13-50-20260907","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"28","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R14-50-20260907","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.2174\/138161211798157586","article-title":"Experimental strategies in autoimmunity: antagonists of cytokines and their receptors, nanocarriers, inhibitors of immunoproteasome, leukocyte migration and protein kinases","volume":"17","author":"Fierabracci","year":"2011","journal-title":"Curr Pharm Des"},{"key":"R15-50-20260907","first-page":"92","article-title":"The proteasome inhibitor bortezomib inhibits the release of NF\u03baB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients","volume":"27","author":"van der Heijden","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R16-50-20260907","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1159\/000334955","article-title":"The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB\/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture","volume":"120","author":"Hainz","year":"2012","journal-title":"Nepron Exp Nephrol"},{"key":"R17-50-20260907","doi-asserted-by":"crossref","first-page":"e34587","DOI":"10.1371\/journal.pone.0034587","article-title":"Proteasome inhibitor bortezomib ameliorates intestinal injury in mice","volume":"7","author":"Yanaba","year":"2012","journal-title":"PLoS One"},{"key":"R18-50-20260907","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"R19-50-20260907","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/ard.2008.097709","article-title":"Bortezomib attenuates murine collagen-induced arthritis","volume":"68","author":"Lee","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R20-50-20260907","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2014.248","article-title":"Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP)","volume":"50","author":"Snarski","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:03:29Z","timestamp":1788797009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00050"}},"subtitle":["A case report and review of the literature"],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":20,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005760","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}